PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
7628183-0	1995	Acetylcholinesterase inhibition by zifrosilone: pharmacokinetics and pharmacodynamics.	zifrosilone	35-46	acetylcholinesterase (Cartwright blood group)	Homo sapiens	0-20	
7628183-1	1995	OBJECTIVE: To determine the pharmacokinetics, pharmacodynamics and safety of the acetylcholinesterase inhibitor zifrosilone in healthy male volunteers.	zifrosilone	112-123	acetylcholinesterase (Cartwright blood group)	Homo sapiens	81-101	
7628183-9	1995	For doses > or = 200 mg, an Emax pharmacodynamic model was used to describe the relationship between zifrosilone plasma concentration and red blood cell acetylcholinesterase inhibition (Emax = 83.8%; EC50 = 0.65 ng/ml).	zifrosilone	104-115	acetylcholinesterase (Cartwright blood group)	Homo sapiens	156-176	
7628183-10	1995	CONCLUSIONS: Zifrosilone showed dose-dependent pharmacokinetics after oral administration and was effective in causing selective inhibition of red blood cell acetylcholinesterase.	zifrosilone	13-24	acetylcholinesterase (Cartwright blood group)	Homo sapiens	158-178